Previous 10 | Next 10 |
Lexicon Pharmaceuticals (NASDAQ: LXRX ) -54% . More news on: Lexicon Pharmaceuticals, Inc., Obalon Therapeutics, Inc., Exact Sciences Corporation, Stocks on the move, Read more ...
KalVista Pharmaceuticals (NASDAQ: KALV ) initiated with Outperform rating and $31 (83% upside) price target at SVB Leerink. More news on: KalVista Pharmaceuticals, Inc., Gilead Sciences, Inc., Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
Lexicon Pharmaceuticals ’ ( LXRX ) tortuous path to success in the diabetes market took another big hit late on Friday July 26, when Sanofi ( SNY ) issued a press release containing a brief summation of top-line results of three Phase III Type 2 diabetes studies of Zynquista and no...
THE WOODLANDS, Texas,, July 26, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), received preliminary topline results from Sanofi for three Phase 3 trials of Zynquista™ (sotagliflozin) in adults living with type 2 diabetes from the InSynchrony clinical ...
After mixed results in two Phase 3 studies, Sanofi (NASDAQ: SNY ) has decided to terminate its collaboration with Lexicon Pharmaceuticals (NASDAQ: LXRX ) to develop, manufacture and commercialize Zynquista (sotagliflozin) for controlling blood sugar levels in type 1 and 2 diabetics. More...
THE WOODLANDS, Texas, July 25, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2019 financial results on Thursday, August 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a...
THE WOODLANDS, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of clinical data for sotagliflozin will be presented at the upcoming 79 th American Diabetes Association (ADA) Scientific Sessions in San Francisco, Califo...
The FDA approves AstraZeneca's (NYSE: AZN ) Qternment XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended-release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control in adults with type-2 diabetes (T2D). More news on: AstraZeneca PLC, E...
Fool me once, shame on you. Fool me twice, shame on me. Disappoint investors over a period of decades? Well, then you’re Lexicon Pharmaceuticals ( LXRX ). Yes, that’s snarky and mean, and not everything that has happened to this company is the fault of management, but in terms ...
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2019 Results Earnings Conference Call May 1, 2019, 08:00 AM ET Company Participants Kimberly Lee - Head, Investor Relations and Corporate Strategy Lonnel Coats - President and Chief Executive Officer Pablo Lapuerta - Executive Vice Presiden...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...